Dr Bedke discusses quality of life data from the findings from the CREST Trial, which he presented at ASCO 2025.

Patient-reported outcomes (PROs) revealed that quality of life was preserved in patients receiving sasanlimab combined with bacillus Calmette-Guérin (BCG) compared to BCG alone in BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC).

Despite statistically significant differences in some measures, none reached the threshold for clinical meaningfulness. Urinary symptoms and treatment-related discomfort remained comparable across treatment arms.

These findings support the use of sasanlimab with BCG, showing no detrimental impact on QoL while offering improved efficacy.

Watch this interview with Prof Thomas PowlesTo learn more about the efficacy data from this trial.